Acción REGN REGENERON PHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Gobernanza Regeneron Pharmaceuticals, Inc.

Acciones

REGN

US75886F1075

Biotecnología e investigación médica

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 24/01/2025 		Varia. Cinco días. Varia. 1 de enero.
675,79 USD -2,71 % Gráfico intradía de Regeneron Pharmaceuticals, Inc. -0,85 % -5,13 %
22/01 REGENERON PHARMACEUTICALS, INC. : Obtiene una recomendación de compra de RBC Capital Markets ZM
16/01 REGENERON PHARMACEUTICALS, INC. : UBS da una recomendación neutral ZM

Comité Ejecutivo: Regeneron Pharmaceuticals, Inc.

Director
Funciones ocupadasDesde
Leonard Schleifer

Leonard Schleifer

72 años

Chief Executive Officer 08/01/1988
Founder 08/01/1988
President 08/01/1988
George Yancopoulos

George Yancopoulos

65 años

Chief Tech/Sci/R&D Officer 01/01/2001
Founder 08/01/1988
President 01/01/2001
Mark Volpe

Mark Volpe

Comptroller/Controller/Auditor 01/01/2012
Patrice Gilooly

Patrice Gilooly

Chief Operating Officer 01/01/1998
Bob McCowan

Bob McCowan

Chief Tech/Sci/R&D Officer -
Maya Bermingham

Maya Bermingham

General Counsel 01/01/2015
Andrew Murphy

Andrew Murphy

67 años

Chief Tech/Sci/R&D Officer 01/01/2019
Johnathan Lancaster

Johnathan Lancaster

Chief Tech/Sci/R&D Officer 01/01/2019
Jason Pitofsky

Jason Pitofsky

48 años

Comptroller/Controller/Auditor 05/02/2024
Melissa Lozner

Melissa Lozner

Compliance Officer 01/01/2022
Joseph LaRosa

Joseph LaRosa

66 años

General Counsel 06/09/2011
Corporate Secretary 06/09/2011
Neil Stahl

Neil Stahl

68 años

Chief Tech/Sci/R&D Officer 01/01/2015
Ned Braunstein

Ned Braunstein

General Counsel 01/01/2009
Sally A. Paull

Sally A. Paull

Human Resources Officer 01/01/2016
Christopher Fenimore

Christopher Fenimore

54 años

Director of Finance/CFO 05/02/2024
Ryan Crowe

Ryan Crowe

Investor Relations Contact -

Composición del Consejo de Administración: Regeneron Pharmaceuticals, Inc.

Administrador
ComitésDesde
George Yancopoulos

George Yancopoulos

65 años

Chairman 09/06/2023
Christine Poon

Christine Poon

72 años

Executive Committee 01/09/2006
Finance Committee Chair
Governance Committee
Compensation Committee Chair 16/11/2010
Finance Committee 05/05/2011
Audit Committee
Nominating Committee
David Schenkein

David Schenkein

67 años

Governance Committee 01/05/2015
Nominating Committee 01/05/2015
Compensation Committee
Governance Committee Chair
Nominating Committee Chair
Bonnie Bassler

Bonnie Bassler

62 años

Governance Committee 12/09/2016
Compensation Committee 30/07/2020
Governance Committee Chair
Nominating Committee Chair
N. Coles

N. Coles

64 años

Executive Committee 18/03/2011
Audit Committee 17/02/2017
Arthur Ryan

Arthur Ryan

82 años

Audit Committee 01/01/2003
Governance Committee Chair 01/01/2003
George Sing

George Sing

75 años

Compensation Committee 08/01/1988
Audit Committee Chair 08/01/1988
Huda Zoghbi

Huda Zoghbi

70 años

Compensation Committee 12/09/2016
Joseph Goldstein

Joseph Goldstein

84 años

Governance Committee 14/06/2019
Michael Brown

Michael Brown

84 años

Governance Committee 01/06/1991
Kathryn Guarini

Kathryn Guarini

53 años

Audit Committee 08/09/2023
Craig Thompson

Craig Thompson

72 años

Director/Board Member 03/10/2022
Independent Dir/Board Member 03/10/2022
Leonard Schleifer

Leonard Schleifer

72 años

Chairman 09/06/2023

Últimos Nombramientos: Regeneron Pharmaceuticals, Inc.

BridgeBio Pharma, Inc. anuncia el nombramiento de Thomas Trimarchi, Ph.D., como presidente y director de operaciones 23/07/24 CI
Regeneron Pharmaceuticals, Inc. Nombra a Jason Pitofsky Contralor, se espera que ocurra el 5 de febrero de 2024 31/01/24 CI
Regeneron Pharmaceuticals, Inc. Nombra a Philip Gregory Vicepresidente Senior y Director de Regeneron Cell Medicines 30/01/24 CI
El director financiero de Regeneron Pharmaceuticals se jubilará en febrero 11/09/23 MT
Regeneron dice que el director financiero Landry se jubilará en febrero 08/09/23 RE
Regeneron Pharmaceuticals, Inc. Anuncia la Jubilación de Robert E. Landry, Vicepresidente Ejecutivo de Finanzas, en febrero de 2024 08/09/23 CI
Regeneron Pharmaceuticals, Inc. Anuncia Cambios en la Junta Directiva 08/09/23 CI
Más noticias

Antiguos Directivos y Administradores: Regeneron Pharmaceuticals, Inc.

Insider
Funciones ocupadas
DesdeHasta
Robert Landry
Robert Landry
Director of Finance/CFO 03/10/2013 05/02/2024
Corporate Officer/Principal 09/09/2013 03/10/2013
Marc Tessier-Lavigne
Marc Tessier-Lavigne
Director/Board Member 21/11/2011 01/09/2023
Independent Dir/Board Member 21/11/2011 01/09/2023
David Weinreich
David Weinreich
Private Equity Investor 01/02/2016 01/08/2023
P. Vagelos
P. Vagelos
Chairman 01/01/1995 09/06/2023
Harold Brakewood
Harold Brakewood
Corporate Officer/Principal 01/12/2015 01/12/2021
James Cassidy
James Cassidy
Corporate Officer/Principal 01/02/2020 01/08/2021
Marcella Ruddy
Marcella Ruddy
Corporate Officer/Principal 01/06/2016 01/06/2021
Neil Graham
Neil Graham
Corporate Officer/Principal 01/01/2009 01/01/2020
Jay Markowitz
Jay Markowitz
Corporate Officer/Principal 05/01/2017 01/01/2020
Ke Andrew Yuan
Ke Andrew Yuan
Corporate Officer/Principal 01/01/2015 01/01/2019
Manisha A. Narasimhan
Manisha A. Narasimhan
Investor Relations Contact 01/09/2011 01/11/2018
Aaron Ondrey
Aaron Ondrey
Corporate Officer/Principal 01/03/2010 01/11/2018
Phillip Gutry
Phillip Gutry
Corporate Officer/Principal 01/06/2015 01/10/2018
Jesper Gromada
Jesper Gromada
Corporate Officer/Principal 01/07/2012 01/10/2018
Charles A. Baker
Charles A. Baker
Director/Board Member 01/02/1989 08/06/2018
Independent Dir/Board Member 01/02/1989 08/06/2018
Robert J. Terifay
Robert J. Terifay
Corporate Officer/Principal 26/02/2007 05/01/2018
Peter Powchik
Peter Powchik
Corporate Officer/Principal 01/10/2006 01/01/2018
Pamela A. Trail
Pamela A. Trail
Corporate Officer/Principal 01/08/2010 01/03/2017
Catherine Stehman-Breen
Catherine Stehman-Breen
General Counsel 01/01/2015 01/03/2017
William J. Sasiela
William J. Sasiela
Corporate Officer/Principal 01/01/2010 01/01/2017
Douglas S. McCorkle
Douglas S. McCorkle
Comptroller/Controller/Auditor 01/05/1998 31/12/2016
Kevin Bailey
Kevin Bailey
Private Equity Investor 01/10/1991 01/01/2016
Robert Alexander Ingram
Robert Alexander Ingram
Director/Board Member 04/04/2014 10/11/2015
Independent Dir/Board Member 11/03/2015 10/11/2015
Murray Goldberg
Murray Goldberg
Chief Administrative Officer 01/03/1995 31/03/2015
Director of Finance/CFO 01/03/1995 03/10/2013
Treasurer 01/03/1995 08/05/2013
Eric M. Shooter
Eric M. Shooter
Director/Board Member 08/01/1988 30/01/2014
Founder 08/01/1988 30/01/2014
Independent Dir/Board Member 08/01/1988 30/01/2014
Corporate Officer/Principal 08/01/1988 02/09/2009
Hala Mirza
Hala Mirza
Public Communications Contact 01/01/2014 -
Julie Clark
Julie Clark
Corporate Officer/Principal 01/05/2011 01/10/2012
Carrie Brownstein
Carrie Brownstein
Corporate Officer/Principal - 01/08/2012
Jim Tripp
Jim Tripp
Director/Board Member 01/01/2007 01/01/2012
Daniel Brims
Daniel Brims
Corporate Officer/Principal 31/07/2011 31/07/2011
Stuart A. Kolinski
Stuart A. Kolinski
General Counsel 01/09/2000 -
Corporate Secretary 01/09/2000 -
Michael Aberman
Michael Aberman
Investor Relations Contact 23/03/2010 -
Randall G. Rupp
Randall G. Rupp
Corporate Officer/Principal 01/07/1991 02/04/2008
Imogene Dunn
Imogene Dunn
Corporate Officer/Principal 01/01/2003 01/01/2008
Beth Levine
Beth Levine
Compliance Officer 01/01/2008 01/09/2022
Corporate Officer/Principal 01/01/2008 -
Alain Thibault
Alain Thibault
Chief Tech/Sci/R&D Officer 02/09/2009 14/12/2011
Corporate Officer/Principal 26/02/2007 02/09/2009
Michael E. Faerm
Michael E. Faerm
Corporate Officer/Principal 01/10/2004 01/10/2004
Merdad Parsey
Merdad Parsey
Chief Tech/Sci/R&D Officer 01/01/2002 01/01/2004
Kremena Simitchieva
Kremena Simitchieva
Sales & Marketing 01/01/2004 -
Hao Zhou
Hao Zhou
Chief Tech/Sci/R&D Officer - 31/12/2001
Fred Middleton
Fred Middleton
Director/Board Member 01/01/1988 01/01/2001
Director of Finance/CFO 01/01/1988 01/01/2001
William G. Roberts
William G. Roberts
Chief Tech/Sci/R&D Officer 01/05/1999 -
General Counsel 01/05/1999 -
Denny Lanfear
Denny Lanfear
Corporate Officer/Principal 01/01/1991 01/01/1999
Prasad Inampudi
Prasad Inampudi
Corporate Officer/Principal 31/12/1998 31/12/1998
Hans-Peter Guler
Hans-Peter Guler
Corporate Officer/Principal 01/04/1998 -
Peter S. DiStefano
Peter S. DiStefano
Corporate Officer/Principal 01/01/1991 01/01/1997
Ronald M. Lindsay
Ronald M. Lindsay
Corporate Officer/Principal 01/01/1997 01/01/1997
Christopher Chapman
Christopher Chapman
Chief Tech/Sci/R&D Officer 01/01/1992 01/01/1994
Stephen P. Squinto
Stephen P. Squinto
Corporate Officer/Principal 01/01/1989 01/01/1992
Alfred G. Gilman
Alfred G. Gilman
Director/Board Member 08/01/1988 -
Founder 08/01/1988 -
Independent Dir/Board Member 08/01/1988 -
Corporate Officer/Principal 08/01/1988 02/09/2009
Carrie Murray
Carrie Murray
Corporate Officer/Principal - -
Brendan Classon
Brendan Classon
Corporate Officer/Principal - -
Robert Lisicki
Robert Lisicki
Corporate Officer/Principal - -
Gene Zhu
Gene Zhu
Corporate Officer/Principal - -
Joseph Ricculli
Joseph Ricculli
Public Communications Contact - -
Justin Holko
Justin Holko
Investor Relations Contact - -
Alexandra Bowie
Alexandra Bowie
Public Communications Contact - -
Eric S. Furfine
Eric S. Furfine
Corporate Officer/Principal - -
Arleen Goldenberg
Arleen Goldenberg
Public Communications Contact - -
Peter G. Dworkin
Peter G. Dworkin
Public Communications Contact 15/12/2009 -
Paul F. Lubetkin
Paul F. Lubetkin
General Counsel - -
Corporate Secretary - -
Fredric D. Price
Fredric D. Price
Chief Administrative Officer - -
Director of Finance/CFO - -
Joseph Pantginis
Joseph Pantginis
Corporate Officer/Principal - -
Catharine E. Johnson
Catharine E. Johnson
Corporate Officer/Principal - -
Matt I. Hermann
Matt I. Hermann
Corporate Officer/Principal - -
Weng Tao
Weng Tao
Corporate Officer/Principal - -
Charles Poole
Charles Poole
Public Communications Contact - -
Sondra Smyrnios
Sondra Smyrnios
Corporate Officer/Principal - -
Potoula Gjidija
Potoula Gjidija
Public Communications Contact - -
Paul Lin
Paul Lin
Corporate Officer/Principal - -
Christian Rommel
Christian Rommel
Chief Tech/Sci/R&D Officer - -
Corporate Officer/Principal - -
Steven E. Buchholz
Steven E. Buchholz
Corporate Officer/Principal - -
Sean Stevens
Sean Stevens
Corporate Officer/Principal - -
Terence E. Ryan
Terence E. Ryan
Corporate Officer/Principal - -
Avner Ingerman
Avner Ingerman
Corporate Officer/Principal - -
Janet van Adelsberg
Janet van Adelsberg
Corporate Officer/Principal - -
Greg DiPasquale
Greg DiPasquale
Corporate Officer/Principal - -
Elizabeth Floegel
Elizabeth Floegel
Corporate Officer/Principal - -

Distribución por Edad de los Ejecutivos

Paridad de género

Hombre 29
Mujer 7

De los cuales Comité Ejecutivo

Hombre 12
Mujer 4

De los cuales Directores

Hombre 12
Mujer 1
ESG MSCI
A

ESG

Medio ambiente
Social
Gobernanza
Polémica

Perfil de la empresa

Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. se especializa en la investigación, el desarrollo, la producción y la venta de medicamentos utilizados en el tratamiento de enfermedades oftalmológicas e inflamatorias y cánceres. Las ventas netas se desglosan por tipo de ingresos de la siguiente manera: - ingresos por venta de productos (56,6%); - ingresos por acuerdos de colaboración (40,4%): colaboración con Sanofi (58,1% de los ingresos), Bayer (29,1%) y Roche (12,8%); - otros (3%): principalmente ingresos por venta de licencias tecnológicas y servicios de investigación subcontratados. A finales de 2022, el grupo contaba con una cartera de aproximadamente 35 productos en desarrollo clínico.
Empleados
14.165
Sector
Biotecnología e investigación médica
Agenda
04/02/2025 - Q4 2024 Publicación de resultados
Más información sobre la empresa

Salida de Personas Clave

P. Vagelos
-
P. Vagelos

Chairman

01/01/1995 09/06/2023

  1. Bolsa de valores
  2. Acciones
  3. Acción REGN
  4. Empresa Regeneron Pharmaceuticals, Inc.
  5. Gobernanza
Estados Unidos

MarketScreener is also available in this country: United States.

Switch edition
Seguir con la edición actual